Albert Hofmann’s first LSD experience in 1943 was, in the book’s account, the world’s first LSD trip and the only one undertaken without prior expectations. Its importance lies not in a settled explanation of what he experienced, but in the uncertainty it opened: Hofmann could not tell whether he had encountered madness or transcendence, yet immediately saw the compound’s potential for neurology and psychiatry. That combination of bewilderment and scientific possibility helped launch a worldwide investigation into what LSD might do.

An Experience Without a Script

Hofmann’s trip stood apart from the experiences that followed because he approached it without expectations about what LSD would mean. The book emphasizes that later psychedelic experiences are highly shaped by what participants are told to anticipate: a spiritual encounter, temporary insanity, access to the collective unconscious, or some other kind of revelation. Hofmann’s uncertainty between madness and transcendence therefore marks the event as an unusually open interpretive starting point, before a body of expectations had accumulated around the drug.

The experience did not resolve into a single explanation. Hofmann was left unsure how to understand it, but that uncertainty did not prevent him from recognizing its possible significance. His response joined the first-person strangeness of the trip to a researcher’s sense that the compound could matter to neurology and psychiatry.

From Discovery to a Research Invitation

Hofmann worked for Sandoz when he discovered LSD. Rather than keeping the compound’s possible uses within the company, Sandoz offered to provide Delysid, its brand name for LSD-25, free of charge to researchers who requested it. The company used a broad definition of researcher: therapists could qualify if they agreed to write up their clinical observations. The policy effectively invited investigators across the world to test possible applications and report what they found.

This arrangement extended well beyond Hofmann’s initial experience. From 1949 to 1966, Sandoz’s free-supply policy remained more or less unchanged, and the book identifies it as a major cause of the first wave of psychedelic research. A single investigator’s encounter thus became the starting point for a dispersed inquiry, conducted by researchers and therapists who were still trying to determine what kind of substance LSD was and what it might be useful for.

A Drug with Competing Meanings

When LSD entered psychiatry in 1950, its effects on patients and on researchers who tried it themselves seemed so novel that scientists spent much of the following decade struggling to fit these experiences into existing accounts of the mind and established methods of psychiatry and psychotherapy. The question was not merely what LSD did, but how to interpret what people reported under its influence. Hofmann’s first trip had supplied no settled answer; the wider research effort inherited that interpretive problem.

Beginning in 1953, the CIA conducted its own classified research into psychedelics and confronted questions of application and meaning from a different institutional position. Its investigators considered whether LSD might serve as a truth serum, a mind-control agent, or a chemical weapon. This parallel inquiry underscores how far the drug’s possible uses ranged, without making the CIA’s program a consequence of Hofmann’s personal experience.

The First Wave and Its End

Sandoz’s research policy helped sustain an unusually broad period of investigation, but it did not last indefinitely. In 1966, alarmed by the controversy surrounding its experimental drug, the company abruptly withdrew Delysid from circulation. The withdrawal brought the first wave of psychedelic research to a close. Hofmann’s 1943 trip therefore stands at the beginning of a history that moved from an unprecedented, hard-to-interpret experience to international clinical and scientific inquiry, and then to a sharp interruption.